Early-Stage Biotechs: What’s Essential and What’s Not

You are a CxO at an early-stage BioPharma company. You have succeeded in obtaining your first round of funding, and those investors and your small team are excited about the prospects of your unique therapy for patient outcomes. That said, you are losing sleep each night. As you toss and turn, three key questions seem to haunt you:

1. How do I get into the clinic?
2. How do I get the right people for our team?
3. How do I meet milestones to keep raising funds?

Even as you grasp at potential answers to these questions, sleep continues to elude you as you realize that the questions are interrelated; answers to one seem to depend on the answers to others. And on it goes, late into the night.

Here at Tunnell, we have found that successful early-stage BioPharmas institute required capabilities to address the three questions above by focusing on the following:

• Creating an integrated development program roadmap
• Utilizing flexible staffing and recruiting models
• Executing detailed plans that follow the roadmap

BioPharmas may avoid operational problems and unneces